Healthcare Realty (HR) Q4 2025 earnings review
Operational Turnaround Complete, Balance Sheet Reset
Healthcare Realty ended its 'transformational' 2025 with strong operational momentum. Same-store cash NOI growth accelerated to 5.5% in Q4, driven by high retention (82.7%) and occupancy gains. Crucially, the company completed its aggressive deleveraging plan, selling $1.2 billion in assets to bring Net Debt/Adjusted EBITDA down to 5.4x (from >6x a year ago). However, the cost of this restructuring is visible in the earnings growth profile: FY26 Normalized FFO guidance ($1.58-$1.64) implies flat performance vs. FY25 ($1.61) as the dilution from asset sales offsets operational gains.
🐂 Bull Case
The portfolio is performing at peak levels. Same-store cash NOI growth hit 5.5% (a multi-year high), and leasing spreads remain positive (+3.7%). With retention over 80%, the 'operations-oriented' culture pivot is delivering results.
The leverage overhang is resolved. Net Debt/EBITDA dropped to 5.4x, well within the target range. The new $600M commercial paper program and $1.4B in liquidity provide flexibility to shift from defense to offense.
🐻 Bear Case
While operations are improving, FFO per share is treading water. FY26 guidance ($1.61 mid) is identical to FY25 actuals. The massive asset sale program ($1.2B) has hollowed out the immediate earnings growth wedge.
While stabilized assets are performing, the company noted a 'sequential lease up of over 500 bps' in redevelopment, but overall occupancy remains a grind. The reliance on 'lease-up' upside carries execution risk if demand softens.
⚖️ Verdict: 🟢
Bullish. Management executed exactly what they promised: they fixed the balance sheet and accelerated operations. While 2026 FFO is flat due to asset sale dilution, the quality of earnings is significantly higher (lower leverage, better asset mix). The company is now positioned for sustainable growth.
Key Themes
Operational Acceleration (SS NOI)
Accelerating. The pivot to an operations-focused culture is empirically working. Same Store Cash NOI growth accelerated sequentially throughout the year: 2.3% (Q1) -> 5.1% (Q2) -> 5.4% (Q3) -> 5.5% (Q4). This was driven by solid pricing power (+3.7% cash leasing spreads) and high retention (82.7%).
Successful Deleveraging
Stable/Success. The company completed $1.2 billion in asset sales through Feb 2026. This aggressive capital recycling brought Net Debt/Adj. EBITDA down from 6.4x in Q1 to 5.4x in Q4. The balance sheet is now 'fixed,' removing the primary bear argument from 2024.
FFO Growth Pause (Dilution)
Stagnant. Despite the operational wins, the math of selling $1.2 billion in assets (mostly at ~6.7% cap rates) to pay down debt creates an earnings hole. FY26 Normalized FFO guidance is $1.58-$1.64, with the midpoint ($1.61) flat against FY25 actuals. Investors looking for bottom-line growth must wait for 2027.
Leasing Velocity
Accelerating. Leasing volume remains robust. Q4 saw 1.5 million square feet executed, including 316,000 square feet of new leases. For the full year, the company executed 5.8 million square feet. The ability to maintain high retention (82.7%) while pushing rates (+3.7%) indicates strong demand for outpatient medical space.
Capital Structure Evolution
New. The company established an inaugural commercial paper program ($600M size). Combined with the extension of the $1.5B revolver to 2030, HR has significantly diversified its financing alternatives, reducing reliance on the bond market for short-term liquidity needs.
Other KPIs
Stable. Consistent with Q3 ($0.41) and Q2 ($0.41) despite the headwind from Q3/Q4 asset sales. The company successfully offset dilution through operational improvements.
Stable. FAD payout ratio stands at 75% for the quarter (dividend $0.24 vs FAD $0.32/sh implied). This is a healthy coverage ratio, validating the Q2 dividend cut decision.
Decelerating (Improving). Down from 6.1x at the start of the year. The company used $1.2B in disposition proceeds to repay $650M in term loans and $250M in notes, achieving its leverage target ahead of schedule.
Guidance
Stable. The midpoint ($1.61) is exactly flat compared to FY25 Actuals ($1.61). This reflects the 'clean' run rate after shedding $1.2B in assets. While not showing growth, it indicates the operational engine is strong enough to fully offset the loss of NOI from sold assets.
Decelerating slightly. The guidance range represents a slight moderation from the red-hot 5.5% achieved in Q4 25, but the midpoint (4.0%) remains well above historical averages (typically 2-3%).
Accelerating. A significant improvement from the FY25 GAAP loss of ($0.71). This is primarily driven by lower impairment charges and reduced interest expense following debt repayment.
Key Questions
Pivot to Offense
With leverage now at 5.4x and a new commercial paper program in place, when does the company plan to shift from net dispositions to net acquisitions, and what are the target markets?
Redevelopment Yields
You mentioned 'significant progress' in redevelopment with 500 bps sequential lease-up. Can you quantify the stabilized yield on cost for these projects and the timeline to reach full stabilization?
Expense Inflation
G&A savings were a key driver in 2025 (run-rate reduced by $10M). As we look to 2026, are there further efficiency levers to pull, or should we expect expense growth to normalize?